GRI Bio Featured in "Why Now" On-Demand Video Webcast
Globe Newswire (Thu, 27-Aug 9:01 AM ET)
JTC Team Releases Virtual Investor "Why Now" On-Demand Conference Featuring Nine Public Company CEOs
ACCESS Newswire (Thu, 27-Aug 9:01 AM ET)
Globe Newswire (Mon, 24-Aug 9:05 AM ET)
Globe Newswire (Thu, 18-Jun 8:31 AM ET)
Market Chameleon (Wed, 28-Jan 4:03 AM ET)
GRI Bio Bolsters Pipeline With New U.S. Patent for Novel Compound Structures
Market Chameleon (Mon, 26-Jan 4:26 AM ET)
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
Gri Bio trades on the NASDAQ stock market under the symbol GRI.
As of September 4, 2026, GRI stock price climbed to $2.88 with 7,034,249 million shares trading.
GRI has a beta of 1.45, meaning it tends to be more sensitive to market movements. GRI has a correlation of 0.01 to the broad based SPY ETF.
GRI has a market cap of $6.30 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, GRI traded as high as $77,102.63 and as low as $1.36.
The top ETF exchange traded funds that GRI belongs to (by Net Assets): VXF.
GRI has underperformed the market in the last year with a return of -93.0%, while SPY returned +20.8%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in GRI shares. However, GRI has outperformed the market in the last 3 month and 2 week periods, returning +43.3% and +72.5%, while SPY returned +2.4% and +1.0%, respectively. This indicates GRI has been having a stronger performance recently.
GRI support price is $2.11 and resistance is $2.47 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GRI shares will trade within this expected range on the day.